XNAS
IMRN
Market cap214kUSD
Jul 09, Last price
1.26USD
1D
-5.26%
1Q
58.89%
Name
Immuron Ltd
Chart & Performance
P/E
—
P/S
1.61
EPS
—
Div Yield, %
—
Shrs. gr., 5y
5.54%
Rev. gr., 5y
23.67%
Revenues
7m
+48.63%
Net income
-5m
L-24.81%
CFO
-6m
L+4.37%
Notes
No notes on this company yet
Write a private note on this company, for your eyes only
Profile
Immuron Limited, an Australian biopharmaceutical firm founded in 1994 and headquartered in Carlton, is dedicated to the exploration, advancement, and worldwide commercialization of polyclonal antibodies. Operating across two divisions—Research and Development, and Hyperimmune Products—the company serves markets in Australia, Israel, Canada, the United States, and other international regions. Its current product portfolio includes Travelan, an over-the-counter remedy aimed at reducing the likelihood of travelers' diarrhea and minor gastrointestinal complaints, which also functions as a dietary supplement for digestive well-being and gut protection. Another offering, Protectyn, is an immune supplement formulated to bolster healthy digestive function and liver support. Beyond its commercialized products, Immuron is actively progressing several pipeline candidates. Travelan (IMM-124E) is currently undergoing a Phase III registration trial in the United States for the prevention of travelers' diarrhea, alongside a Phase II field trial for the same indication, and has demonstrated antiviral efficacy against SARS-CoV-2. Concurrently, IMM-529 is in Phase I/IIa clinical trials, targeting patients with recurrent Clostridium difficile infections. The company has also established key research alliances, including an agreement with the Naval Medical Research Center to develop and clinically evaluate a therapeutic agent against Campylobacter and enterotoxigenic Escherichia coli infections, and a collaborative effort with the Walter Reed Army Institute of Research to create an oral treatment for shigellosis.
Valuation
Title AUD in thousands, except ratios and share amounts | FY | FY | FY | FY | FY | FY | FY | FY | FY |
|---|---|---|---|---|---|---|---|---|---|
| 2025‑06 | 2024‑06 | 2023‑06 | 2022‑06 | 2021‑06 | 2020‑06 | 2019‑06 | 2018‑06 | 2017‑06 | |
| Income | |||||||||
Revenues | |||||||||
Cost of revenue | |||||||||
Unusual Expense (Income) | |||||||||
NOPBT | |||||||||
NOPBT Margin | |||||||||
Operating Taxes | |||||||||
Tax Rate | |||||||||
NOPAT | |||||||||
Net income | |||||||||
Dividends | |||||||||
Dividend yield | |||||||||
Proceeds from repurchase of equity | |||||||||
BB yield | |||||||||
| Debt | |||||||||
Debt current | |||||||||
Long-term debt | |||||||||
Deferred revenue | |||||||||
Other long-term liabilities | |||||||||
Net debt | |||||||||
| Cash flow | |||||||||
Cash from operating activities | |||||||||
CAPEX | |||||||||
Cash from investing activities | |||||||||
Cash from financing activities | |||||||||
FCF | |||||||||
| Balance | |||||||||
Cash | |||||||||
Long term investments | |||||||||
Excess cash | |||||||||
Stockholders' equity | |||||||||
Invested Capital | |||||||||
ROIC | |||||||||
ROCE | |||||||||
| EV | |||||||||
Common stock shares outstanding | |||||||||
Price | |||||||||
Market cap | |||||||||
EV | |||||||||
EBITDA | |||||||||
EV/EBITDA | |||||||||
Interest | |||||||||
Interest/NOPBT | |||||||||